The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management
Abstract
Disease overview:Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation.Diagnosis:PV is defined by a JAK2 mutation, whose absence, combined with normal or increased serum erythropoietin level, makes the diagnosis unlikely. Differential diagnosis in ET includes reactive thrombocytosis, chronic myeloid leukemia, and prefibrotic myelofibrosis. Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations occur in approximately 55%, 25%, and 3% of ET patients, respectively. The same molecular markers are also present in prefibrotic myelofibrosis, which needs to be morphologically distinguished from ET.Survival and leukemic/fibrotic transformation:Median survivals are ∼14 years for PV and 20 years for ET; the corresponding values for younger patients are 24 and 33 years. Life‐expectancy in ET is inferior to the control population.JAK2/CALR mutational status does not affect survival in ET. Risk factors for survival in ET and PV include advanced age, leukocytosis, and thrombosis. Leukemic transformation rates at 20 years are estimated at <10% for PV and 5% for ET; fibrotic transformation rates are slightly higher.Thrombosis risk stratification:Current risk stratification in PV and ET is designed to estimate the likelihood of recurrent thrombosis: high‐risk is defined by the presence of age >60 years or presence of thrombosis history; low‐risk is defined by the absence of both of these two risk factors. Recent data consider JAK2 V617F and cardiovascular risk factors as additional risk factors. Presence of extreme thrombocytosis might be associated with acquired von Willebrand syndrome (AvWS) and, therefore, risk of bleeding.Risk‐adapted therapy:The main goal of therapy in PV and ET is to prevent thrombohemorrhagic complications. In low risk patients, this is accomplished by the use of low‐dose aspirin and phlebotomy (hematocrit target <45%) in PV. In high risk (for thrombosis) patients, treatment with hydroxyurea is additionally recommended. Treatment with busulfan or interferon‐α is usually effective in hydroxyurea failures and the additional value of JAK inhibitor therapy in such cases is limited. Screening for AvWS is recommended before administrating aspirin, in the presence of extreme thrombocytosis. Am. J. Hematol. 90:163–173, 2015. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationSomatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Self-citationTefferi, A., & Vardiman, J. W. (2008) · Leukemia · doi:10.1038/sj.leu.2404955 · Cited by 1,002
Self-citationHydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Self-citationHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Self-citationEuropean consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele, J., Kvasnicka, H. M., Facchetti, F., Franco, V., van der Walt, J. D., & Orazi, A. (2005) · PubMed · Cited by 762
Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationClonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 634
Barbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Self-citationRumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A. S., Milosevic, J. D., Them, N. C. C., Berg, T., Elena, C., Casetti, I. C., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539098 · Cited by 602
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 548
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citationBarosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationIncreased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy
Berk, P. D., Goldberg, J. D., Silverstein, M. N., Weinfeld, A., Donovan, P. B., Ellis, J. T., Landaw, S. A., Laszlo, J., Najean, Y., Pisciotta, A. V., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102193040801 · Cited by 492
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
Elliott, M. A., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05277.x · Cited by 473
Self-citationCarobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Vannucchi, A. M., Antonioli, E., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339002 · Cited by 456
Self-citationFinazzi, G. (2005) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 431
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationRotunno, G., Mannarelli, C., Guglielmelli, P., Pacilli, A., Pancrazzi, A., Pieri, L., Fanelli, T., Bosi, A., & Vannucchi, A. M. (2014) · Blood · doi:10.1182/blood-2013-11-538983 · Cited by 416
Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3471 · Cited by 373
Sterkers, Y., Preudhomme, C., Laı̈, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 372
Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370
Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H.-M., Kralovics, R., & Petrides, P. E. (2013) · Blood · doi:10.1182/blood-2012-07-443770 · Cited by 330
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationWolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Self-citationPardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 294
Self-citationPassamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Kvasnicka, H. M., Ruggeri, M., Randi, M. L., Gangat, N., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403279 · Cited by 277
Self-citationAlvarez-Larrán, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V., Hernández-Boluda, J.-C., Ayats, R., Salvador, C., Muntañola, A., Bellosillo, B., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263319 · Cited by 244
Fruchtman, S. M., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D., & Wasserman, L. R. (1997) · PubMed · Cited by 239
Alvarez-Larrán, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J.-C., Ferrer-Marín, F., Angona, A., Gómez, M., Muiña, B., Guillén, H., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387787 · Cited by 234
Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., Pocaterra, D., Ragazzoni, E., Rolandi, G., Rocca, B., et al. (2012) · Blood · doi:10.1182/blood-2011-06-359224 · Cited by 222
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., et al. (2008) · Blood · doi:10.1182/blood-2008-01-135897 · Cited by 222
Self-citationTefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 217
Self-citationTefferi, A., Wassie, E. A., Guglielmelli, P., Gangat, N., Belachew, A. A., Lasho, T. L., Finke, C., Ketterling, R. P., Hanson, C. A., Pardanani, A., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23743 · Cited by 213
Self-citationGangat, N., Wolanskyj, A. P., McClure, R. F., Li, C.-Y., Schwager, S., Wu, W., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404500 · Cited by 208
Self-citationTefferi, A., & Elliott, M. (2007) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-976165 · Cited by 197
Self-citationMichiels, J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U., & van Vliet, H. V. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-949664 · Cited by 169
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
Kiladjian, J.-J., Chomienne, C., & Fenaux, P. (2008) · Leukemia · doi:10.1038/leu.2008.280 · Cited by 169
Barbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., et al. (2014) · Blood · doi:10.1182/blood-2014-07-591610 · Cited by 161
Self-citationBarbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009) · Blood · doi:10.1182/blood-2009-02-206797 · Cited by 159
Self-citationBrecqueville, M., Rey, J., Bertucci, F., Coppin, E., Finetti, P., Carbuccia, N., Cervera, N., Gelsi‐Boyer, V., Arnoulet, C., Gisserot, O., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.21960 · Cited by 158
Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz, P., Girodon, F., Donnard, M., Latger‐Cannard, V., Dobo, I., Boiret, N., Lecron, J., Binquet, C., Barro, C. D., Hermouet, S., et al. (2004) · PubMed · Cited by 156
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Guglielmelli, P., Pancrazzi, A., Bergamaschi, G., Rosti, V., Villani, L., Antonioli, E., Bosi, A., Barosi, G., & Vannucchi, A. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06565.x · Cited by 153
Masked polycythemia Vera (mPV): Results of an international study
Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Carobbio, A., Rumi, E., Randi, M. L., Betozzi, I., Vannucchi, A. M., Pieri, L., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23585 · Cited by 151
Self-citationDNMT3A mutations in myeloproliferative neoplasms
Stegelmann, F., Bullinger, L., Schlenk, R. F., Paschka, P., Griesshammer, M., Blersch, C., Kuhn, S., Schauer, S., Döhner, H., & Döhner, K. (2011) · Leukemia · doi:10.1038/leu.2011.77 · Cited by 151
Najean, Y., & Rain, J. (1997) · Blood · doi:10.1182/blood.v89.7.2319 · Cited by 149
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J. L., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404069 · Cited by 144
Tefferi, A., & Fonseca, R. (2002) · Blood · doi:10.1182/blood.v99.7.2627 · Cited by 127
Self-citationJAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
Pardanani, A. D., Vannucchi, A. M., Passamonti, F., Cervantes, F., Barbui, T., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.269 · Cited by 125
Self-citationSchmitt-Graeff, A. H., Teo, S.-S., Olschewski, M., Schaub, F. X., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U., & Skoda, R. C. (2007) · Haematologica · doi:10.3324/haematol.11581 · Cited by 121
Polycythemia Vera and the Myeloproliferative Disorders
Petitt, R. M. (1995) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63955-4 · Cited by 120
GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
Mead, A. J., Rugless, M. J., Jacobsen, S. E. W., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1200349 · Cited by 117
Calreticulin mutations and long-term survival in essential thrombocythemia
Tefferi, A., Wassie, E. A., Lasho, T. L., Finke, C. M., Belachew, A. A., Ketterling, R. P., Hanson, C. A., Pardanani, A. D., Gangat, N., & Wolanskyj, A. P. (2014) · Leukemia · doi:10.1038/leu.2014.148 · Cited by 116
Self-citationEvidence and expertise in the management of polycythemia vera and essential thrombocythemia
Finazzi, G., & Barbui, T. (2008) · Leukemia · doi:10.1038/leu.2008.177 · Cited by 112
Self-citationBoyd, E. M., Bench, A. J., Goday‐Fernández, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08083.x · Cited by 106
Presence of calreticulin mutations in JAK2-negative polycythemia vera
Broséus, J., Park, J.-H., Carillo, S., Hermouet, S., & Girodon, F. (2014) · Blood · doi:10.1182/blood-2014-06-583161 · Cited by 98
Barbui, T., Thiele, J., Carobbio, A., Guglielmelli, P., Rambaldi, A., Vannucchi, A. M., & Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23694 · Cited by 84
Self-citationFinazzi, G., Carobbio, A., Guglielmelli, P., Cavalloni, C., Salmoiraghi, S., Vannucchi, A. M., Cazzola, M., Passamonti, F., Rambaldi, A., & Barbui, T. (2014) · Blood · doi:10.1182/blood-2014-08-596676 · Cited by 82
Self-citationÁlvarez‐Larrán, A., Martinez-Aviles, L. M., Hernández‐Boluda, J. C., Ferrer‐Marín, F., Antelo, M. L., Burgaleta, C., Mata, M. I., Xicoy, B., Martínez‐Trillos, A., Gómez‐Casares, M. T., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2152-7 · Cited by 81
Bonicelli, G., Abdulkarim, K., Mounier, M., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12117 · Cited by 81
Grießhammer, M., Struve, S., & Harrison, C. N. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-942763 · Cited by 78
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76
Liu, K., Martini, M., Rocca, B., Amos, C. I., Teofili, L., Giona, F., Ding, J., Komatsu, H., Larocca, L. M., & Skoda, R. C. (2009) · Haematologica · doi:10.3324/haematol.2009.005918 · Cited by 60
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
Shvidel, L., Sigler, E., Haran, M. Z., Klepfish, A., Duek, A., Berrébi, A., & Shtalrid, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404743 · Cited by 55
Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
Östör, A. J. K. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0964-3 · Cited by 39
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Kuriakose, E. T., Gjoni, S., Wang, Y. L., Baumann, R., Jones, A. V., Cross, N. C. P., & Silver, R. T. (2013) · Haematologica · doi:10.3324/haematol.2013.087742 · Cited by 37
Li, T. M. W. Y., Gignac, M. A. M., Wells, G. A., Shen, S. W., & Westhovens, R. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.015 · Cited by 14
Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction
Tefferi, A. (2008) · Acta Haematologica · doi:10.1159/000140629 · Cited by 9
Self-citationDudler, J., Tuerk, R., Handschin, T., & Forster, A. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13849 · Cited by 5
Cited by
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Spivak, J. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1406186 · Cited by 404
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice
Wang, W., Liu, W., Fidler, T., Wang, Y., Tang, Y., Woods, B., Welch, C., Cai, B., Silvestre-Roig, C., Ai, D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313283 · Cited by 262
Metadata
- Authors
- Tefferi, A., & Barbui, T.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2015-01-21
- Volume
- 90
- Issue
- 2
- Pages
- 162-173
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1959044271
- Cited by
- 270
- References
- 81
- FWCI
- 27.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.